GENB — Generate Biomedicines Income Statement
0.000.00%
Last trade - 00:00- $1.43bn
- $1.44bn
- $31.89m
Annual income statement for Generate Biomedicines, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2024 December 31st | 2025 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG |
| Status: | Final | Final |
| Revenue | ||
| Total Revenue | 20.5 | 31.9 |
| Selling / General / Administrative Expenses | ||
| Research And Development | ||
| Depreciation and Amortization | ||
| Total Operating Expenses | 217 | 267 |
| Operating Profit | -197 | -235 |
| Total Net Non Operating Interest Income / Expense | ||
| Other Net Non Operating Costs | ||
| Net Income Before Taxes | -181 | -223 |
| Provision for Income Taxes | ||
| Net Income After Taxes | -181 | -223 |
| Minority Interest | ||
| Net Income Before Extraordinary Items | ||
| Net Income | -174 | -203 |
| Adjustments to Net Income | ||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | -214 | -250 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -1.68 | -1.96 |
| Dividends per Share |